Federal Register / Vol. 60, No. 62 / Friday, March 31, 1995 / Notices 16655

National Library of Medicine; Notice of

Meetings of the Board of Regents and

the Extramural Programs

Subcommittee

Pursuant to Pub. L. 92–463, notice is

hereby given of the meeting of the Board

of Regents of the National Library of

Medicine on May 23–24, 1995, in the

Board Room of the National Library of

Medicine, 8600 Rockville Pike,

Bethesda, Maryland. The Extramural

Programs Subcommittee will meet on

May 22 in Conference Room B, Building

38A, from 2 p.m. to approximately 3:30

p.m., and will be closed to the public.

The meeting of the Board will be open

to the public from 9 a.m. to

approximately 4:30 p.m. on May 23 and

from 9 a.m. to adjournment on May 24

for administrative reports and program

discussions. Attendance by the public

will be limited to space available.

Individuals who plan to attend and

need special assistance, such as signlanguage interpretation or other

reasonable accommodations, should

contact Mrs. Karin Colton at 301–496–

4621 two weeks before the meeting.

In accordance with provisions set

forth in secs. 552b(c)(4), 552b(c)(6), Title

5, U.S.C. and sec. 10(d) of Pub. L. 92–

463, the entire meeting of the

Extramural Programs Subcommittee on

May 22 will be closed to the public from

2 p.m. to approximately 3:30 p.m., and

the regular Board meeting on May 23

will be closed from approximately 4:30

p.m. to 5 p.m. for the review,

discussion, and evaluation of individual

grant applications. These applications

and the discussion could reveal

confidential trade secrets or commercial

property, such as patentable material,

and personal information concerning

individuals associated with the

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Mr. Robert B. Mehnert, Chief, Office

of Inquiries and Publications

Management, National Library of

Medicine, 8600 Rockville Pike,

Bethesda, Maryland 20894, Telephone

Number: 301–496–6308, will furnish a

summary of the meeting, rosters of

Board members, and other information

pertaining to the meeting.

(Catalog of Federal Domestic Assistance

Program No. 93.879—Medical Library

Assistance, National Institutes of Health.)

Dated: March 27, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–7992 Filed 3–30–95; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Neurological

Disorders and Stroke; Notice of

Meeting, Board of Scientific

Counselors

Pursuant to Pub. L. 92–463, notice is

hereby given of the meeting of the Board

of Scientific Counselors, National

Institute of Neurological Disorders and

Stroke, Division of Intramural Research,

on June 4–6, 1995, at the National

Institutes of Health, Medical Board

Room, Building 10, Rm. 2C116, 9000

Rockville Pike, Bethesda, Maryland,

20892.

This meeting will be open to the

public from 8:30 a.m. to 12:20 p.m. and

from 1:30 p.m. to 5:00 p.m. on June 5th,

and from 8:30 a.m. to 2:10 p.m. on June

6th, to discuss program planning and

program accomplishments. Attendance

by the public will be limited to space

available.

In accordance with the provisions set

forth in section 552b(c)(6), Title 5,

U.S.C. and section 10(d) of Pub. L. 92–

463, the meeting will be closed to the

public from 8 p.m. to 10 p.m. on June

4th and from 2:10 p.m. until

adjournment on June 6th, for the review,

discussion and evaluation of individual

programs and projects conducted by the

NINDS. The programs and discussions

include consideration of personnel

qualifications and performances, the

competence of individual investigators

and similar items, the disclosure of

which would constitute a clearly

unwarranted invasion of personal

privacy.

The Freedom of Information

Coordinator, Ms. Mary Whitehead,

Federal Building, Room 1012, 7550

Wisconsin Avenue, Bethesda, MD

20892, telephone (301) 496–9231 or the

Acting Executive Secretary, Dr. Harold

Gainer, Acting Director, Division of

Intramural Research, NINDS, Building

10, Room 5N214, National Institutes of

Health, Bethesda, MD 20892, telephone

(301) 496–4297, will furnish a summary

of the meeting and a roster of committee

members upon request. Individuals who

plan to attend and need special

assistance, such as sign language

interpretation or other reasonable

accommodations, should contact the

Acting Executive Secretary in advance

of the meeting.

(Catalog of Federal Domestic Assistance

Program No. 13.853, Clinical Basis Research;

No. 13.854, Biological Basis Research)

Dated: March 27, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–7991 Filed 3–30–95; 8:45 am]

BILLING CODE 4140–01–M

Opportunity For Licensing: HIV–1

Nucleocapsid Protein (p7nc) Capture

Assay

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The National Institutes of

Health (NIH), Department of Health and

Human Services (DHHS), seeks

licensee(s) to develop a novel

immunological capture assay for the

detection of human immunodeficiency

virus (HIV). Scientists at the National

Cancer Institute have identified a new

screening assay based on the detection

in biological samples of p7nc, an HIV

nucleocapsid protein. The assay is free

from interference by antigen-antibody

complexes. Potential uses for this assay

include determining the prognosis of

disease in an HIV-infected person,

monitoring the effectiveness of antiviral

treatment, detecting HIV infection in

infants born to HIV-infected mothers,

and detecting and quantitating HIV in

laboratory experiments, i.e., virus

production, infectivity assays,

neutralization assays and drug

effectiveness assays. NIH intends to

grant the selected firm(s) world-wide

royalty-bearing license(s) to practice the

inventions embodied in U.S. Patent

Application Serial No. 07/967,658 from

Dr. Larry O. Arthur and Dr. Louis E.

Henderson entitled ‘‘HIV Nucleocapsid

Protein Capture Assay and Method of

Use.’’ The patent rights in these

inventions have been assigned to the

United States of America.

SUPPLEMENTARY INFORMATION: The

current antigen capture assays for the

detection of HIV–1 utilize the capsid

antigen p24CA or the matrix protein

p17MA. Antibodies to p24 and p17

found in HIV–1-infected persons

interfere with the assays and limit their

utility. The AIDS Vaccine Development

Program at the National Cancer

Institute-Frederick Cancer Research and

Development Center has found that

antibodies to p7 are not prevalent in

HIV–1-infected individuals. This

observation coupled with the fact that

p7 is found in equal molar quantities to

p24 in the virus, makes p7 an ideal

candidate for an HIV antigen capture

assay. A p7 capture assay has been

developed and p7 assays of sera of

seropositive individuals to which HIV–

1 is added demonstrate that HIV–1 can

be detected. Similar experiments using

commercial p24 assays are negative. The

assay may be used for samples

containing bodily fluids, tissues, or cell

culture fluid. Because the assay is

capable of measuring the nucleocapsid

protein concentration, which correlates